Stealth BioTherapeutics Pushing Innovative New Approach to Treating Eye Diseases
Reenie McCarthy, CEO of Stealth BioTherapeutics, introduces the company’s early-stage clinical program testing mitochondrial medicine as treatment for ophthalmic conditions. McCarthy details three ongoing clinical trials targeting dry AMD, Leber’s Hereditary Optic Neuropathy, and Fuchs’ Corneal Dystrophy.